Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Updated Meta-Analysis of Phase III Randomized Controlled Trials (RCTs) to Evaluate the Incidence of Second Primary Malignancies (SPMs) in Patients with Multiple Myeloma (MM) Treated with Isatuximab

Hazem Aboaid, Kevin Nguyen, Daniel Thomas Jones, Ramaditya Srinivasmurthy, Rishi Kumar Nanda, Kyaw Zin Thein, Thura Win Htut

Blood (2024) 144 (Supplement 1): 7866.

https://doi.org/10.1182/blood-2024-211236

Published: 2024

Journal Articles

Efficacy of Isatuximab Combination Regimens in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials

Hazem Aboaid, Ramaditya Srinivasmurthy, Daniel Thomas Jones, Kevin Nguyen, Rishi Kumar Nanda, Kyaw Zin Thein, Thura Win Htut

Blood (2024) 144 (Supplement 1): 7036.

https://doi.org/10.1182/blood-2024-209018

Published: 2024

Journal Articles

Updated Meta-Analysis of Phase III Randomized Controlled Trials (RCTs) to Evaluate the Incidence of Pneumonia, Upper Respiratory Tract Infections (URTIs) and Venous Thromboembolism (VTE) in Patients with Multiple Myeloma Treated with Isatuximab

Daniel Thomas Jones, Hazem Aboaid, Ramaditya Srinivasmurthy, Kevin Nguyen, Rishi Kumar Nanda, Kyaw Zin Thein, Thura Win Htut

Blood (2024) 144 (Supplement 1): 2390.

https://doi.org/10.1182/blood-2024-211295

Published: 2024

Journal Articles

Viral Genome Scan for Analysis of CMV-Specific CD8+ T Cells in Normal and Immunocompromised Individuals.

Thomas J. Manley, MD, Tori Yamamoto, Lisa Luy, Thomas Jones, PhD, Michael Boeckh, MD, Adam P. Geballe, MD, Stanley R. Riddell, MD

Blood (2007) 110 (11): 1068.

https://doi.org/10.1182/blood.V110.11.1068.1068

Published: 2007

Journal Articles

Immune evasion proteins of human cytomegalovirus do not prevent a diverse CD8 + cytotoxic T-cell response in natural infection

Thomas J. Manley, Lisa Luy, Thomas Jones, Michael Boeckh, Helen Mutimer, Stanley R. Riddell

Blood (2004) 104 (4): 1075–1082.

https://doi.org/10.1182/blood-2003-06-1937

Published: 2004

NARROW

Updated Meta-Analysis of Phase III Randomized Controlled Trials (RCTs) to Evaluate the Incidence of Second Primary Malignancies (SPMs) in Patients with Multiple Myeloma (MM) Treated with Isatuximab

Efficacy of Isatuximab Combination Regimens in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials

Updated Meta-Analysis of Phase III Randomized Controlled Trials (RCTs) to Evaluate the Incidence of Pneumonia, Upper Respiratory Tract Infections (URTIs) and Venous Thromboembolism (VTE) in Patients with Multiple Myeloma Treated with Isatuximab

Viral Genome Scan for Analysis of CMV-Specific CD8+ T Cells in Normal and Immunocompromised Individuals.

Immune evasion proteins of human cytomegalovirus do not prevent a diverse CD8 + cytotoxic T-cell response in natural infection

Email alerts

ASH Publications

American Society of Hematology

Updated Meta-Analysis of Phase III Randomized Controlled Trials (RCTs) to Evaluate the Incidence of Second Primary Malignancies (SPMs) in Patients with Multiple Myeloma (MM) Treated with Isatuximab

Efficacy of Isatuximab Combination Regimens in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials

Updated Meta-Analysis of Phase III Randomized Controlled Trials (RCTs) to Evaluate the Incidence of Pneumonia, Upper Respiratory Tract Infections (URTIs) and Venous Thromboembolism (VTE) in Patients with Multiple Myeloma Treated with Isatuximab

Viral Genome Scan for Analysis of CMV-Specific CD8+ T Cells in Normal and Immunocompromised Individuals.

Immune evasion proteins of human cytomegalovirus do not prevent a diverse CD8 + cytotoxic T-cell response in natural infection

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only